Product Name: Met (1000-1006) pY1003
Product Number: PE-04BAG00
| Size: | 200 µg | Price: | 30.00 | |
| 1 mg | $US | 60.00 |
Peptide Name: Met (1000-1006) pY1003
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases and for epitope mapping of phosphosite-specific antibodies. The peptide sequence is located in the region between the Transmembrane domain and the protein kinase catalytic domain. Y1003 phosphorylation stimulates phosphotransferase activity. Phosphorylation regulates cell growth, receptor desensitization, protein stabililzation, ubquitination, protein and molecular association.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: SVD-pY-RAT
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases and for epitope mapping of phosphosite-specific antibodies. The peptide sequence is located in the region between the Transmembrane domain and the protein kinase catalytic domain. Y1003 phosphorylation stimulates phosphotransferase activity. Phosphorylation regulates cell growth, receptor desensitization, protein stabililzation, ubquitination, protein and molecular association.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: SVD-pY-RAT
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 889.83 Da
Peptide Purity Percent after Synthesis and Purification: >80
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Peptide Molecular Mass Calculated: 889.83 Da
Peptide Purity Percent after Synthesis and Purification: >80
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Scientific Background: Met (HGFR) is a protein-tyrosine kinase of the TK group and Met family. It is activated by binding hepatocyte growth factor (HGF), which induces dimerization and autophosphorylation. Phosphorylation of Y1003 increases phosphotransferase activity and induces interaction with Cbl. Phosphorylation of Y1230 and Y1235 increases phosphotransferase activity. Phosphorylation of Y1234 increases phosphotransferase activity and induces interaction with Grb2. Phosphorylation of S985 inhibits phosphotransferase activity. Phosphorylation of Y1349 inhibits phosphotransferase activity, but induces interaction with FAK, Gab1, Grb2, Met, PIK3R1, PLCG1 and Src. Met mediates scattering, proliferation, survival, and morphogenesis of cells. Some immediate regulators that bind to Met after activation with HGF include PLCG1, PIK3R1, GRB2, SRC, STAT3 or the adapter GAB1. Met is a known oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. The active form of the protein kinase normally acts to promote tumour cell proliferation. Hepatocellular carcinoma (HCC) occurs with higher risk in those that have chronic HCV (hepatitis C virus) or HBV (hepatitis B virus) infection, or aflatoxin exposure in diet, or alcohol-induced cirrhosis, or another form of cirrhosis.
© Kinexus Bioinformatics Corporation 2017